Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Steadymed Ltd    STDY   IL0011348997

STEADYMED LTD

(STDY)
SummaryQuotesNewsCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
Most relevant news about STEADYMED LTD
2018UNITED THERAPEUTICS CORPORATION : Completes Acquisition Of SteadyMed Ltd.
PR
2018SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial..
GL
2018SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics
GL
2018STEADYMED : HSR Act Waiting Period Terminated for United Therapeutics' Acquisiti..
PR
2018HSR Act Waiting Period Terminated for United Therapeutics' Acquisition of Ste..
GL
2018Monteverde & Associates PC Announces An Investigation Of SteadyMed Ltd. - STD..
PR
2018SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial ..
GL
2018THE LAW OFFICES OF VINCENT WONG : Notifies Investors of an Investigation into St..
BU
2018Brower Piven Commences an Investigation into the Proposed Sale of SteadyMed L..
BU
2018WEISSLAW LLP : Investigates SteadyMed Ltd.
PR
2018Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether..
BU
2018Brower Piven Commences An Investigation Into The Proposed Sale Of SteadyMed L..
BU
2018Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whethe..
BU
2018STEADYMED (STDY) ALERT : Johnson Fistel Investigates Proposed Sale of SteadyMed ..
PR
2018STEADYMED : United Therapeutics To Acquire SteadyMed Ltd.
PR
2018United Therapeutics to Acquire SteadyMed Ltd.
GL
2018SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year ..
GL
2017SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission
GL
2017SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federa..
GL
2017SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate..
GL
2017Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possibl..
BU
2017GLANCY PRONGAY & MURRAY LLP : Continues Investigation on Behalf of SteadyMed Ltd..
BU
2017SteadyMed Receives Notice of Allowance for its European Patent Relating to En..
GL
2017SteadyMed Submits Type A Meeting Request Package to FDA
GL
2017Goldberg Law PC Announces an Investigation of SteadyMed Ltd.
BU
2017Law Offices of Howard G. Smith Continues Investigation on Behalf of SteadyMed..
BU
2017Goldberg Law PC Announces an Investigation of SteadyMed Ltd.
BU
2017GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of SteadyMed Ltd..
BU
2017INVESTOR ALERT : Kaplan Fox Announces Investigation Of SteadyMed Ltd.
PR
2017STEADYMED LTD. Girard Gibbs Investigates Potential Securities Law Violations
BU
2017Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possibl..
BU
2017Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SteadyMed Ltd. ..
PR
2017Pomerantz Law Firm Investigates Claims On Behalf of Investors of SteadyMed Lt..
PR
2017SteadyMed Receives Refusal to File Letter from FDA for Trevyent® New Drug App..
GL
2017SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporat..
GL
2017SteadyMed to Present at the 2017 Wedbush PacGrow Healthcare Conference
GL
2017SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs
GL
2017SteadyMed to Present at the 2017 JMP Securities Life Sciences Conference
GL
2017SteadyMed Raises Additional Capital from Key Institutional Shareholder
GL
2017SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate..
GL
2017SteadyMed Receives USPTO Notice of Allowance for Patent Related to Key PatchP..
GL
2017SteadyMed Raises $30 Million in Private Placement
GL
2017SteadyMed Completes Clinical Validation Study of Trevyent®
GL
2017SteadyMed Receives Favorable Ruling in Inter Partes Review against United The..
GL
2017SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year ..
GL
2017SteadyMed Outlines Strategic Goals and Priorities for 2017 and Provides Updat..
GL
2016SteadyMed Hires Pulmonary Hypertension Veteran to Lead Patient Advocacy and C..
GL
2016SteadyMed Provides Update on IPR Hearing
GL
2016SteadyMed Celebrates Phenomenal People With Pulmonary Hypertension During PH ..
GL
2016SteadyMed Provides Corporate Update and Reports Third Quarter 2016 Financial ..
GL
2016SteadyMed to Present at the 25th Annual Credit Suisse Healthcare Conference
GL
2016SteadyMed to Present at the Annual Ladenburg Thalmann 2016 Healthcare Confere..
GL
2016SteadyMed to Present at the 18th Annual Rodman & Renshaw Global Investment Co..
GL
2016SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities
GL
2016SteadyMed Provides Corporate Update and Reports Second Quarter 2016 Financial..
GL
2016SteadyMed Raises up to $32 Million in Private Placement
GL
2016SteadyMed to Present at the 2016 JMP Securities Life Sciences Conference
GL
2016UPDATE -- SteadyMed and the Pulmonary Hypertension Association Launch Campaig..
GL
2016SteadyMed and the Pulmonary Hypertension Association Launch Campaign to Highl..
GL
2016SteadyMed Provides Corporate Update and Reports First Quarter 2016 Financial ..
GL
2016SteadyMed Announces Public Availability of PTAB Decision to Institute Inter P..
GL
2016SteadyMed to Host an Analyst and Investor Reception
GL
2016SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Pat..
GL
2016SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year ..
GL
2016SteadyMed to Present at RBC Capital Markets 2016 Global Healthcare Conference
GL
2016SteadyMed to Present at 18th Annual BIO CEO & Investor Conference
GL
2016Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® ..
GL
2016SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of ..
GL
2015SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associ..
GL
2015SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Result..
GL
2015SteadyMed to Report Recent Developments and Third Quarter 2015 Financial Resu..
GL
2015SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for..
GL
2015SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent
GL
2015SteadyMed to Participate in Upcoming Investor Conferences
GL
2015STEADYMED : to Provide Insights on Recent Corporate Developments and Report Seco..
PU
1  2Next